Details for Patent: 10,548,880
✉ Email this page to a colleague
Which drugs does patent 10,548,880 protect, and when does it expire?
Patent 10,548,880 protects ENVARSUS XR and is included in one NDA.
This patent has thirty-six patent family members in sixteen countries.
Summary for Patent: 10,548,880
Title: | Solid dispersions comprising tacrolimus |
Abstract: | A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability. |
Inventor(s): | Holm; Per (Vanlose, DK) |
Assignee: | VELOXIS PHARMACEUTICALS A/S (Copenhagen, DK) |
Application Number: | 15/676,727 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 10,548,880
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS | ⤷ Sign Up | ||||
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-001 | Jul 10, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT | ⤷ Sign Up | ||||
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS | ⤷ Sign Up | ||||
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-002 | Jul 10, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT | ⤷ Sign Up | ||||
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS | ⤷ Sign Up | ||||
Veloxis Pharms Inc | ENVARSUS XR | tacrolimus | TABLET, EXTENDED RELEASE;ORAL | 206406-003 | Jul 10, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,548,880
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Denmark | 2003 01232 | Aug 29, 2003 |
Denmark | 2003 01837 | Dec 11, 2003 |
Denmark | 2004 00079 | Jan 21, 2004 |
Denmark | 2004 00463 | Mar 23, 2004 |
Denmark | 2004 00467 | Mar 23, 2004 |
International Family Members for US Patent 10,548,880
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 473003 | ⤷ Sign Up | |||
Austria | 531368 | ⤷ Sign Up | |||
Australia | 2004267909 | ⤷ Sign Up | |||
Australia | 2004267910 | ⤷ Sign Up | |||
Brazil | PI0413927 | ⤷ Sign Up | |||
Brazil | PI0414000 | ⤷ Sign Up | |||
Canada | 2537041 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |